Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cytosorbents (CTSO) EBITDA (2016 - 2025)

Historic EBITDA for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$2.9 million.

  • Cytosorbents' EBITDA rose 4074.53% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$14.1 million, marking a year-over-year increase of 3726.51%. This contributed to the annual value of -$16.8 million for FY2024, which is 4745.96% up from last year.
  • Cytosorbents' EBITDA amounted to -$2.9 million in Q3 2025, which was up 4074.53% from -$3.6 million recorded in Q2 2025.
  • In the past 5 years, Cytosorbents' EBITDA ranged from a high of -$2.9 million in Q1 2021 and a low of -$9.6 million during Q4 2021
  • Moreover, its 5-year median value for EBITDA was -$5.4 million (2021), whereas its average is -$5.9 million.
  • In the last 5 years, Cytosorbents' EBITDA crashed by 26297.88% in 2021 and then soared by 6036.51% in 2024.
  • Over the past 5 years, Cytosorbents' EBITDA (Quarter) stood at -$9.6 million in 2021, then skyrocketed by 33.52% to -$6.4 million in 2022, then plummeted by 48.01% to -$9.4 million in 2023, then skyrocketed by 60.37% to -$3.7 million in 2024, then increased by 23.25% to -$2.9 million in 2025.
  • Its EBITDA stands at -$2.9 million for Q3 2025, versus -$3.6 million for Q2 2025 and -$3.9 million for Q1 2025.